ANIX stock forecast
Our latest prediction for Anixa Biosciences, Inc.'s stock price was made on the Jan. 14, 2020 when the stock price was at 3.18$.
In the short term (2weeks), ANIX's stock price should underperform the market by -0.48%. During that period the price should oscillate between -10.15% and +16.07%.
In the medium term (3months), ANIX's stock price should underperform the market by -11.87%. During that period the price should oscillate between -40.79% and +37.22%.Get email alerts
About Anixa Biosciences, Inc.
Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body's immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -0.59$ per share.
The book value per share is 0.28$
Three months stock forecastJan. 14, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|